Clinical Trial Update: HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial of HIF-2 alpha inhibitor PT2385 in recurrent glioblastoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• PT2385

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Recurrent Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-21